X0206 3 2021-08-11 0 0001824893 Surrozen, Inc./DE SRZN 0001771994 Vanhove Geertrui C/O SURROZEN, INC. 171 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 22834 D Employee Stock Option (right to buy) 0.22 2029-05-16 Common Stock 108902 D Employee Stock Option (right to buy) 1.89 2031-02-22 Common Stock 26347 D Received pursuant to the Business Combination Agreement (the "BCA"), dated April 15, 2021, by and among the Issuer (fka "Consonance-HFW Acquisition Corp"), Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. (the "Original Surrozen"). Under the terms of the BCA, among other things, Merger Sub merged with and into the Original Surrozen, with Original Surrozen surviving as a wholly-owned subsidiary of the Issuer (the "Business Combination"), the Original Surrozen changed its name to Surrozen Operating, Inc., and the Issuer changed its name to Surrozen, Inc. In addition, per the terms of the BCA, each share and equity award of the Original Surrozen outstanding as of effective time of the Business Combination was exchanged for shares of the Issuer's Common Stock or comparable equity awards that are settled or are exercisable for shares of the Issuer's Common Stock, as applicable, at the exchange ratio of 0.175648535. Twenty-five percent of the shares subject to the Stock Option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. 1/48th of the shares subject to the Stock Option shall vest on each monthly anniversary of the vesting commencement date over a four-year period. /s/ Sheela Mohan-Peterson, Attorney-in-Fact for Geertrui Vanhove 2021-08-16